NeuroPace Inc Cash Flow Statement
NPCE|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
NeuroPace Inc used $18M in operating cash flow and negative free cash flow of $18M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$27.1M | -$33.0M | -$47.1M | -$36.1M | -$24.3M |
| Depreciation & Amortization | $207.0K | $172.0K | $267.0K | $296.0K | $312.0K |
| Operating Cash Flow | -$17.9M | -$19.7M | -$36.9M | -$24.6M | -$21.6M |
| Capital Expenditures | $306.0K | $173.0K | $603.0K | $384.0K | $62.0K |
| Free Cash Flow | -$18.3M | -$19.9M | -$37.5M | -$25.0M | -$21.7M |
| Share Buybacks | $0 | - | - | - | - |
| FCF Margin | -22.9% | -30.4% | -82.3% | -55.2% | -52.7% |